$SRPT shares plunged almost 55% with the FDA raising concerns | Briefing Document Raises Concerns

Sarepta Tanks, Eteplirsen Briefing Document Raises Concerns

Sarepta Therapeutics (SRPT) shares plunged 55% after the FDA raised concerns related to the Duchenne muscular dystrophy candidate, eteplirsen, in its briefing documents.